Highlights

MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.

Archivi del mese: giugno 2015

MP-E-8-3/1959

Bi-specific humanized antibody against Endosialin and LGALS3BP

Endosialin (aka TEM1 and CD248) is a protein expressed by pericytes of tumor blood vessels and directly on a subset of malignant cells. Blocking Endosialin with antibodies has been shown to inhibit tumor growth and metastasis.

LGALS3BP is a a protein secreted at large amounts by the vast majority of tumor cells, which plays an important role in cell-cell and cell-extracellular matrix adhesion and, recently, as a pro-angiogenic factor.

Use of a bi-specific antibody against Endosialin and LGALS3BP may result in a greater anti-angiogenic and anti-tumor effect than either antibody alone.

Company

R&D

Careers

Business